A subscription to JoVE is required to view this content. Sign in or start your free trial.
We have developed enhancements and updated methods for the existing monocyte-monolayer assay (MMA), in which macrophages are used to help better predict the clinical relevance of red cell alloantibodies in transfusion medicine and immunology. This assay is named the monocyte-macrophage assay (M-MA).
Derived from monocytes in the bone marrow, macrophages are large, innate immune cells that play a major role in clearing dead cells, debris, tumor cells, and foreign pathogens. The phagocytic capacity of monocytes versus macrophages is a concept that is not well understood. Here, we aim to examine a difference in the phagocytosis of monocytes versus macrophages, specifically M1/M2 macrophages, against various opsonized red cells using a modified and updated version of the established monocyte monolayer assay (MMA). Peripheral blood mononuclear cells (PBMCs) were isolated from donor buffy coats. Using purified monocytes, inflammatory M1 and anti-inflammatory M2 macrophages were produced by in vitro culture and polarization. M1/M2 cells were harvested and used in an MMA-like assay, which we refer to as the M-MA, to decipher clinically significant phagocytosis of various red cell antibodies. A phagocytic index (PI) > 5 was deemed clinically significant phagocytosis with the use of monocytes. A phagocytic index (PI) > 12 was deemed clinically significant phagocytosis with the use of M1/M2 macrophages. M2 macrophages demonstrate an increased ability to phagocytose opsonized RBCs compared to monocytes and M1s. The same weak antibody (anti-S) yields significant phagocytosis with only M2 macrophages (PI=43) but not M1s (PI=2) or monocytes (PI=0), and this was demonstrated repeatedly using various antibodies. The use of M2 macrophages instead of monocytes may allow for more accurate results as these cells are more phagocytic, offering further clinical relevance to the assay. Further studies with different antibodies to red blood cells, including validation of the monocyte-macrophage assay (M-MA) with antibodies having known clinical significance, may show the M-MA more useful to help predict clinically significant red cell alloantibodies and transfusion reactions. This method will advance the field of transfusion medicine and immunology.
Predicting transfusion reactions remains a significant challenge in the field of transfusion medicine. Over the past 4 decades, the monocyte-monolayer assay (MMA), pioneered by Tong and Branch1,2, has served as a valuable in vitro cellular assay for predicting the clinical outcome of hemolysis in blood transfusion patients1. Indeed, this assay has been instrumental in distinguishing between clinically significant and insignificant red blood cell (RBC) antibodies2. While monocytes have traditionally been the standard leukocyte used in this assay, our rese....
This research was performed in compliance with institutional guidelines for conducting ethical research involving human subjects. Ethics approval was granted from the Canadian Blood Services Research Ethics Board (REB), approval CBSREB#2023.008. All steps of this protocol are to be carried out in a biosafety cabinet under sterile conditions.
1. Isolation of PBMCs
The results in Figure 1 are consistent with the literature and indicate a successful polarization of macrophages from their M0 state to their subsequent M1/M2 state. M1 and M2 macrophages were cultured for 8 days (6 days with growth factors and 2 days of polarization), and anti-D or anti-k opsonized RBCs were tested (Figure 2). M2 macrophages demonstrate a high phagocytic index compared to M1s with RBCs opsonized by either anti-D (control) or an.......
To ensure the method’s success, one must adhere to the following critical steps: 1) successful M1/M2 polarization, 2) generation of the macrophage layer and RhD+ control 3) quantification of phagocytic index. While our methods state to use isolated monocytes for the cell culture, PBMCs may be used, but we recommend using purified monocytes. It is known that PBMCs contain various cell types, with these cells secreting multiple different cytokines and mediating factors. This may have an impact on the differentia.......
The authors have nothing to disclose.
This work is supported and funded by the Canadian Blood Services Centre for Innovation in Toronto, ON. Research is performed at the Keenan Research Centre for Biomedical Sciences at St. Michaels Hospital in Toronto, ON.
....Name | Company | Catalog Number | Comments |
1X PBS, pH 7.4, without Ca2+/Mg2+ | Wisent Bioproducts | 311-425-CL | Store at 4 degrees or room temperauture |
AccutaseTM | STEMCELL Technologies | 7920 | Cell detachment solution |
ACK Lysis Buffer | STEMCELL Technologies | 07850, 07800 | Store at 4 degrees |
Anti-Human Globulin | NOVACLONE, Immunocor. | N/A | NOVACLONE Anti-igG for IAT testing |
Anti-Rh(D) (WinRho. SDF CDN) | Saol Therapeutics | 1003092 | Any commerical source of Rh immune globin will suffice |
Cell Scraper | UofT Medstore | 83.395 | cell detachement |
Cell Strainer 70uM nylon | Falcon | 352350 | filter of cells |
Chamber slide Nunc. Lab-TekTM II with Cover, RS Glass Slide Sterile | Thermo Fisher Scientific | 154534 | chamber slides for MMA |
Coverslips | VWR | 48393-081 | 24 x 50 mm |
Cytiva Ficoll Paque Plus, density 1.077 g/L | Thermo Fisher Scientific | 17-1440-03 | sepeation of PBMCS from whole blood; density gradient medium |
Elvanol Mounting Medium | N/A | N/A | Dulbecco’s PBS (D-PBS) without Ca2+/Mg2+, 15% (w/v) polyvinyl resin, and 30% (v/v) glycerine. |
Fresh whole blood (ACD tube) or Buffy coat | Canadian Blood Services | May rest at room tempruatre for up to 36 hours | |
Human Recombinant GM-CSF | STEMCELL Technologies | 78015.1 | Cytokine for polarization of M1 macrophages |
Human Recombinant IFN-gamma | STEMCELL Technologies | 78020 | Cytokine for polarization of M1 macrophages |
Human Recombinant IL-4 | STEMCELL Technologies | 78045.1 | Cytokine for polarization of M2 macrophages |
Human Recombinant M-CSF | STEMCELL Technologies | 78057.1 | Cytokine for polarization of M2 macrophages |
ID-CellStab | Bio-Rad | 005650 05740 | RBC cell storage/stabilization solution |
Isolation Medium | N/A | N/A | PBS Ca2+ and Mg2+ free + FBS 2% + 1mM EDTA |
Lipopolysaaracide (LPS) | Sigma Aldrich | L3024-5MG | Cytokine for polarization of M1 macrophages |
Methanol (100%) | N/A | N/A | Fixing of slides |
Monocyte Isolation Kit STEM-cells EasySep Human Monocyte Enrichment Kit without CD16 Depletion | STEMCELL Technologies | 19058 | Isolation of monocytes from PBMCs |
Poly-D-ysine | UofT Medstore | P6407 | Cell attachment solution |
Rh(D) positive R2R2 RBCs | Canadian Blood Services | N/A | Also commerically avaiable |
RPMI-1640 | Wisent Bioproducts | 350-000-CL | supplemented with 10% heat-inactivated FBS,1 mM GlutaMAX supplement, 1 mM HEPES, and 1%penicillin/streptomycin. Store at 4 degrees. |
Trypan Blue solution | Thermo Fisher Scientific | 15250061 | Cell counting solution |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2025 MyJoVE Corporation. All rights reserved